Previous 10 | Next 10 |
Rubius Therapeutics press release (NASDAQ:RUBY): Q4 GAAP EPS of -$0.61 misses by $0.02. As of December 31, 2021, cash and cash equivalents were $225.8M as compared to $176.3M in cash, cash equivalents and investments as of December 31, 2020, For further details see: Rubius Therapeutics ...
First Patient Dosed in Phase 1/2 Clinical Trial of RTX-224 in Patients with Certain Advanced Solid Tumors in January 2022 Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors Continues with No Dose-Limiting Toxicities Observed to Date and an NK Cell Dose Response. Clin...
Gainers: Cumulus Media (NASDAQ:CMLS) +5%. HOOKIPA Pharma (NASDAQ:HOOK) +4%. KemPharm (NASDAQ:KMPH) +4%. Anghami (NASDAQ:ANGH) +4%. Editas Medicine (NASDAQ:EDIT) +4%. Losers: Homology Medicines (NASDAQ:FIXX) -31%. Consumer Portfolio Services (NASDAQ:CPSS) -...
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT PR Newswire CAMBRIDGE, Mass. , Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdepende...
CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...
The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with this event. For further details see: Rubius Therapeutics (RUBY) Investor Presentation IP - Slideshow
CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...
CAMBRIDGE, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...
Continuing Dose Escalation in Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors with No Dose-Limiting Toxicities Observed to Date and an NK Cell Dose Response with Clinical Results Expected in Q1’22 Initial Clinical Results Expected from the Phase 1 Clinical ...
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...
News, Short Squeeze, Breakout and More Instantly...
Rubius Therapeutics Inc. Company Name:
RUBY Stock Symbol:
OTCMKTS Market:
Rubius Therapeutics Inc. Website:
iClick Interactive Asia Group Limited (ICLK) is expected to report for quarter end 2023-09-30 Applied Minerals Inc (AMNL) is expected to report for quarter end 2023-09-30 Banco Do Brasil S.A. ADR (BDORY) is expected to report for Q3 2023 Rubius Therapeutics Inc. (RUBY) is expected to ...
American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Surgalign Holdings Inc. (SRGAQ) is expected to report for quarter end 2023-09-30 MillerKnoll Inc. (MLKN) is expected to report $0.52 for Q2 2024 Ping AN Insurance (Group) Co. of China, Ltd. ADR - Level I...
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...